Details for Patent: 11,253,478

Which drugs does patent 11,253,478 protect, and when does it expire?

Patent 11,253,478 protects ANJESO and is included in one NDA.

This patent has sixteen patent family members in eight countries.

Summary for Patent: 11,253,478

Title:	Reduction of flake-like aggregation in nanoparticulate active agent compositions
Abstract:	This invention is directed to reduction of flake-like aggregation in nanoparticulate compositions. Also encompassed by the invention are compositions comprising a nanoparticulate active agent, at least one surface stabilizer and a flake-like aggregation reducing agent, such as a buffer and a sugar. The nanoparticulate active agent compositions comprise particles of the active agent having an effective average particle size of less than about 2000 nm.
Inventor(s):	Ryde; Niels P. (Malvern, PA), Snyder; Peter (King of Prussia, PA), Liu; Wei (Exton, PA), Slifer; David M. (Downingtown, PA)
Assignee:	Alkermes Pharma Ireland Limited (Dublin, IE)
Application Number:	15/971,616
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 11,253,478

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Baudax	ANJESO	meloxicam	SOLUTION;INTRAVENOUS	210583-001	Feb 20, 2020		DISCN	Yes	No			Y			MANAGEMENT OF MODERATE-TO-SEVERE PAIN BY INJECTION

International Family Members for US Patent 11,253,478

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2010254180
Canada	2763456
European Patent Office	2435027
European Patent Office	3167875
Spain	2609415